All In Biotech

Drug Trial Radar · NCT01248494

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

A Phase Ib Trial of BKM120 (a PI3K Inhibitor) or BEZ235 (a PI3K/mTOR Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Nov 2010

Primary completion

Dec 2012

Study completion May 2016

Sponsor

Lead sponsor
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label phase Ib multi-institution trial that evaluates the safety profile/tolerability and preliminary anti-tumor effect of BKM120 (a PI3K inhibitor) and endocrine therapy combination and BEZ235 (a PI3K/ mTOR inhibitor) and endocrine therapy combination in postmenopausal patients with hormone receptor-positive metastatic breast cancer.

Conditions

  • Metastatic Breast Cancer

Interventions

  • BEZ235Drug

    * Dose level 1: 400mg PO BID * Dose level -1: 400mg PO in AM and 200mg PO in PM * Dose level -2: 200mg PO BID

  • BKM 120Drug

    * Dose Level 1: BKM120, 100 mg PO daily * Dose level -1: BKM120, 80 mg PO daily * Dose Level -2: BKM120, 60 mg PO daily

  • LetrozoleDrug

    All levels: 2.5mg/day PO

  • BKM120Drug

    * Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly * Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly * Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose of BKM120 or BEZ235 given in combination with endocrine therapyTime frame: at 4 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Massachusetts General Hospital, Dana Farber Cancer Center

    Boston, Massachusetts

  • Columbia University Medical Center

    New York, New York

  • Vanderbilt Cool Springs

    Nashville, Tennessee

  • Vanderbilt Breast Center One Hundred Oaks

    Nashville, Tennessee

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.